IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
iBio, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026
$0.76−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
iBio, Inc. revenue by segment
By business segment
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q4 25 | Q3 25 | Q2 25 | Q4 22 | Q3 22 | Q2 22 | Q4 21 | Q3 21 | Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (iBio, Inc.) [Member] | – | – | – | – | – | – | $0 | $1.80M | – | $1.00K | $700.00K | $190.00K | – | – |
| Bioprocessing (iBio CDMO) [Member] | – | – | – | – | – | – | $61.00K | $143.00K | $168.00K | $491.00K | $65.00K | $515.00K | – | – |
| Operating income | Q4 26 | Q3 26 | Q2 26 | Q4 25 | Q3 25 | Q2 25 | Q4 22 | Q3 22 | Q2 22 | Q4 21 | Q3 21 | Q2 21 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (iBio, Inc.) [Member] | – | – | – | – | – | – | -$10.83M | -$6.58M | -$6.95M | -$4.78M | -$4.28M | -$3.13M | – |
| Bioprocessing (iBio CDMO) [Member] | – | – | – | – | – | – | -$6.07M | -$5.61M | -$4.69M | -$4.66M | -$2.93M | -$4.41M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of iBio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.